1. Home
  2. FNWD vs HURA Comparison

FNWD vs HURA Comparison

Compare FNWD & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$33.39

Market Cap

164.2M

Sector

Finance

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.69

Market Cap

144.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
HURA
Founded
1994
2009
Country
United States
United States
Employees
N/A
22
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
164.2M
144.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
FNWD
HURA
Price
$33.39
$2.69
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$37.50
$10.00
AVG Volume (30 Days)
2.8K
1.2M
Earning Date
04-24-2026
05-14-2026
Dividend Yield
1.48%
N/A
EPS Growth
N/A
N/A
EPS
1.88
N/A
Revenue
N/A
N/A
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$17.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.46
$0.41
52 Week High
$39.99
$4.30

Technical Indicators

Market Signals
Indicator
FNWD
HURA
Relative Strength Index (RSI) 37.77 62.35
Support Level $31.52 $2.29
Resistance Level $38.79 $2.74
Average True Range (ATR) 0.75 0.34
MACD -0.17 0.05
Stochastic Oscillator 52.17 65.51

Price Performance

Historical Comparison
FNWD
HURA

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: